Document is current
Any future updates will be listed below
-
Authors
Hu, Sile https://orcid.org/0000-0002-8437-7387
Ferreira, Lino A. F. https://orcid.org/0000-0002-1957-4245
Shi, Sinan https://orcid.org/0000-0001-6935-0429
Hellenthal, Garrett
Marchini, Jonathan https://orcid.org/0000-0003-0610-8322
Lawson, Daniel J. https://orcid.org/0000-0002-5311-6213
Myers, Simon R. https://orcid.org/0000-0002-2585-9626
-
Funding
Funding for this research was provided by:
Wellcome Trust (200186/Z/15/Z, 212284/Z/18/Z, 222334/Z/21/Z, 200186/Z/15/Z, 224575/Z/21/Z, 200186/Z/15/Z)
- License Information
-
More Information
Article History
Received: 16 August 2023
Accepted: 18 November 2024
First Online: 3 February 2025
Competing interests
: S.H. became a full-time employee of Novo Nordisk Ltd during the drafting of this manuscript. J.M. is a current employee and stockholder of Regeneron Pharmaceuticals. The other authors declare no competing interests.
